ReviewRSC advances2026
Smart microdevices for biomedical drug delivery: endogenous stimuli as the key to safer therapeutics.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Smart Mesoporous Silica Nanoparticle-Based Drug Delivery Systems: Recent Advances in Biomedical Applications, Wound Healing and Therapeutic Perspectives.Pharmaceutics · 2026Review
- Edible Fungal Polysaccharide-Liposome: Interfacial Interactions, Structure-Function Relationship, and Emerging Application in Oral Delivery and Functional Foods.International journal of molecular sciences · 2026Review
- Plant-Derived Peptide-Polymer Therapeutics for Cutaneous Infections and Inflammation: Mechanistic Basis, Delivery Design and Translational Considerations.Pharmaceutics · 2026Review
- Review
- Nanorobotic Approaches Against Multidrug-Resistant Infections: Design, Principle, Mechanistic Innovation, Translational Challenges and Biomedical Applications.Molecules (Basel, Switzerland) · 2026Review
- Smart thyroid-regulated drug delivery systems: a review of intelligent biosensor-integrated therapeutics for precision thyroxine replacement.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The landscape of drug delivery has undergone a transformative shift with the emergence of adaptive therapeutics, smart microdevices engineered to respond dynamically to specific physiological or externally applied stimuli. These stimuli-responsive systems represent a significant advancement over conventional delivery methods by offering precise spatiotemporal control over drug release, thereby enhancing therapeutic efficacy and minimizing off-target effects and systemic toxicity. This review delves into the foundational design principles and material innovations that underpin these responsive microdevices. It highlights the role of endogenous stimuli such as pH gradients, temperature fluctuations, enzymatic activity, and redox, ionic, and hypoxia-responsive elements in activating drug release mechanisms. The integration of cutting-edge microfabrication techniques, nanomaterials, and bioinspired architectures has enabled the development of devices that are not only highly sensitive and selective but also capable of navigating complex biological environments. Furthermore, the article explores and examines the challenges associated with scalability, long-term biocompatibility, biosafety, and toxicity of implanted microdevices. Emerging trends such as AI-enhanced feedback loops, wearable biosensors, and closed-loop delivery platforms are discussed as future directions that could redefine personalized medicine. By bridging engineering ingenuity with biomedical imperatives, stimuli-responsive microdevices are poised to revolutionize drug delivery, offering intelligent, patient-centric solutions that adapt in real time to the dynamic needs of the human body. Notably, stimulus-responsive microdevices may soon facilitate localized delivery of imaging contrast agents, pharmaceuticals, genes, and mRNA; enable minimally invasive surgical procedures; and assist in cellular micromanipulation.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.